SG/CALL/VERTEX PHARMACEUTICALS/500/0.1/17.01.25 | Real-time Boerse Frankfurt Warrants 05:11:54 2024-05-17 EDT | ||
| 2.17 EUR | -1.81% |
|
| Current month | +93.86% | ||
| 1 month | +55.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 2.17 | -1.81% |
| 24-05-16 | 2.21 | +1.84% |
| 24-05-15 | 2.17 | +9.60% |
| 24-05-14 | 1.98 | -1.49% |
| 24-05-13 | 2.01 | +9.24% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 05:11 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6E2Y |
| ISIN | DE000SU6E2Y0 |
| Date issued | 2023-12-29 |
| Strike | 500 $ |
| Maturity | 2025-01-17 (246 Days) |
| Parity | 10 : 1 |
| Emission price | 2.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.77 € |
|---|---|
| Lowest since issue | 1.11 € |
| Spread | 0.16 € |
| Spread % | 6.96% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Warrants
- Warrant
